Molecular imaging modalities, such as prostate- specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT), through the quantification of tumor metabolic heterogeneity, provide high-sensitivity support for the staging of high-risk patients (5). The gene discussed is FOLH1; the disease is neoplasm.